Monday, July 20, 2020

Viracta Therapeutics Names Strategic Advisor

San Diego-based precision oncology developer Viracta Therapeutics said this morning that it has appointed Mark A. McCamish, MD, Ph.D. as a strategic advisor to the company. McCamish was most recently President and Chief Executive Officer of Forty Seven Inc., where Viracta said he led through IPO and multiple financings until the acquisition by Gilead for approximately $4.9 Billion. McCamish also has served at Novartis' Sandoz division, PDL BioPharma, Perlegen Sciences, Facet Labs, Amgen Inc. and Abbott Laboratories.